4Berrih AS.Myasthenia gravis,a model of orangspecific autoimmune disease[J].J Autoimmune,1995,8:139.
5Romi F,Skeie GO,Vedeler C,et al.Complement activation by titin and rganodine receptor autoantibodies in myasthenia gravis,a study of IgG subclasses and clinical correlations[J].J Neuroimmunol,2000,111:169.
6Fredrik R,Kristoffersen K,Johan A,et al.The role of complement in myasthenia gravis:serological evidence of complement consumption in vivo[J].Neuroimmunol,2005,158:191.
7Kaminski H,Li Z,Richmonds C,et al.Complement regulators in extraocular muscle and experimental autoimmune myasthenia gravis[J].Exp Neurol,2004,189:333.
8Ptak J,Lochman J.Immunoadsorption therapy and complement activation[J].Trans Aph Sci,2005,32:263.
9Milan B,Isabel I,Marines C,et al.Increased in vitro uptake of the complement C3b in the serum of patients with Guillain-Barre syndrome,myasthenia gravis and dermatomyositis[J].Neuroimmunol,1996,71:227.
10Erdem N,Scott B,Benjamin G,et al.Genetic evidence for involvement of classical complement pathway in induction of experimental autoimmune myasthenia gravis[J].Immunol,2003,171:3847.
